SALIX PHARMACEUTICALS INC - NOTE 2.750% 5/1

CUSIP: 795435AC0

Q3 2014 13F Holders as of 30 Sep 2014

Type / Class
Debt / NOTE 2.750% 5/1
Market price (% of par)
335.96%
Total 13F principal
$336,593,000
Principal change
-$10,125,000
Total reported market value
$1,133,316,000
Number of holders
26
Value change
-$24,983,658
Number of buys
8
Number of sells
9

Quarterly Holders Quick Answers

What is CUSIP 795435AC0?
CUSIP 795435AC0 identifies 795435AC0 - SALIX PHARMACEUTICALS INC - NOTE 2.750% 5/1 in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of SALIX PHARMACEUTICALS INC - NOTE 2.750% 5/1 as of Q3 2014

As of 30 Sep 2014, SALIX PHARMACEUTICALS INC - NOTE 2.750% 5/1 was held by 26 institutional bondholders reporting positions in Form 13F filings. These institutions reported holding $336,593,000 in principal (par value) of the bond. The largest 10 bondholders included BAKER BROS. ADVISORS LP, WOLVERINE ASSET MANAGEMENT LLC, HIGHBRIDGE CAPITAL MANAGEMENT LLC, CITIGROUP INC, FRANKLIN RESOURCES INC, SYMPHONY ASSET MANAGEMENT LLC, Citadel Advisors LLC, LORD, ABBETT & CO. LLC, CAPSTONE INVESTMENT ADVISORS, LLC, and JPMORGAN CHASE & CO. This page lists 26 institutional bondholders reporting positions for the Q3 2014 filing period.
Investor Option Weight % Change % Value $ * Price (% of par) Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.